Deoxynivalenol drives liver injury progression by dysregulating core molecular networks: integrated multi-omics,

Yunfeng Fu1, Sicheng Yang1, Yating Pan1

  • 1Department of Gastroenterology, Jiangxi Provincial Key Laboratory of Digestive Diseases, Jiangxi Clinical Research Center for Gastroenterology, Digestive Disease Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.

Abstract

Insights

Deoxynivalenol (DON) drives liver disease progression by altering key molecular networks and directly interacting with hub proteins. This study reveals novel insights into DON-induced hepatotoxicity and potential biomarkers.

Area of Science:

  • Hepatology and Toxicology
  • Molecular Biology
  • Genomics

Background:

  • Deoxynivalenol (DON) is a foodborne mycotoxin linked to chronic liver disease, cirrhosis, and hepatocellular carcinoma (HCC).
  • The precise role of DON in liver disease pathogenesis remains unclear.
  • This study investigates DON's pathogenic networks using an integrated multi-omics and toxicological approach.

Purpose of the Study:

  • To elucidate the molecular mechanisms underlying DON-induced liver injury.
  • To identify key molecular players and networks involved in DON's progression of liver disease.
  • To provide mechanistic insights into DON-induced hepatotoxicity.

Main Methods:

  • Integration of transcriptomic and toxicogenomics data.
  • Application of differential expression analysis, protein-protein interaction networks, and machine learning.
  • Validation through in vitro (human hepatocytes) and in vivo (mouse models) assays.

Main Results:

  • Five core hub genes (FAT1, CCND1, GADD45G, PHLDA1, FOS) identified as DON-induced liver injury drivers.
  • DON directly binds to hub proteins, causing G2/M phase arrest in hepatocytes.
  • In vivo studies show DON induces hepatic damage and inflammation, correlating with hub protein dysregulation.

Conclusions:

  • Chronic DON exposure promotes liver disease by disrupting molecular networks and interacting with hub proteins.
  • The study offers novel mechanistic insights into DON-induced liver damage.
  • Identified hub proteins and pathways serve as potential biomarkers for DON hepatotoxicity.

Related Concept Videos

Drug Toxicity: Overview01:00

Drug Toxicity: Overview

Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...
247
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
210
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
208
Toxicokinetics: Overview01:21

Toxicokinetics: Overview

Studies that assess how a drug is absorbed, distributed, metabolized, and excreted (ADME) at toxic doses are termed toxicokinetics. Understanding toxicokinetics helps predict adverse drug reactions (ADRs) and manage toxicity in humans.Toxicokinetics differs from pharmacokinetics mainly in the dose levels studied, with toxicokinetics focusing on higher toxic doses. The kinetics at these levels can be non-linear due to altered physiological processes. Toxicodynamics examines the relationship...
253
Bioactivation and Tissue Toxicity01:25

Bioactivation and Tissue Toxicity

Bioactivation is a metabolic process that transforms less reactive substances into highly reactive metabolites, initiating tissue toxicity. This transformation can lead to various toxic effects, including carcinogenesis and teratogenesis. Reactive metabolites are classified into two main types: electrophiles and free radicals.Electrophiles are electron-deficient species and are produced primarily by the enzyme cytochrome P-450 during the metabolism of compounds containing carbon, nitrogen, or...
134
Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
170